UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis
The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.
The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.